Predict your next investment

Incubator/Accelerator
blueprinthealth.org

See what CB Insights has to offer

Investments

88

Portfolio Exits

11

Partners & Customers

1

About Blueprint Health

The Blueprint Health accelerator program is geared towards healthcare companies that want an intensive three-month program to help find customers and capital. Blueprint Health is a Charter Member of the Global Accelerator Network, which was started by TechStars. Selected companies range from two founders with an idea to businesses that have customers, investors and are generating significant revenue.

Blueprint Health Headquarter Location

438 Broadway 2nd Floor

New York, New York, 10013,

United States

646-627-7627

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Blueprint Health News

PathologyWatch Raises $25M to Advance AI-Driven Skincare Research and Diagnostics

Nov 17, 2021

PathologyWatch Raises $25M to Advance AI-Driven Skincare Research and Diagnostics SALT LAKE CITY, November 16, 2021-- PathologyWatch, the leading digital lab and pathology platform for dermatologists, announced today that it has raised $25M in Series B financing with participation from Ceros Capital Markets, Rock Creek Capital, SpringTide, Spark Growth Ventures, Blueprint Health, Blackbrook Management Group, and existing investors. With the new funding, PathologyWatch will broaden its outreach to dermatologists and conduct further research into skincare diagnostics and AI -- allowing patients to receive faster diagnoses and more equitable access to dermatopathology services while enabling labs to work more efficiently and cost-effectively. Additionally, the funding will support operations as the business expands across the country, adding new labs in Texas, Florida, and Arizona. “We are honored that of all the digital dermpath labs available, dermatologists are increasingly choosing to partner with us,” said Dan Lambert, PathologyWatch CEO and cofounder. “As digital dermatopathology continues to grow, it has the potential to reduce the costs of pathology by billions while creating better patient care for everyone across the country. We’re thrilled to be winning so much volume so quickly.” PathologyWatch provides fully interfaced EMR reporting and 24/7 access to digital slides for dermatology clinics. For their clients, this means more efficient workflows and direct access to leading dermatopathologists across the country, with broad insurance coverage. PathologyWatch has successfully integrated laboratory information systems, scanners, digital viewer technology, and EMRs into an end-to-end solution for dermatologists. “PathologyWatch has been disruptive to the market and is digitally transforming the industry in unprecedented ways,” said Mark Goldwasser, CEO of Ceros. “With the need for remote health services during Covid, the distributed network of top-tier dermatopathologists alongside a digital viewer that can be accessed anytime and anywhere could not have come at a more fortuitous time.” “For a dermatology practice to send nearly all skin biopsy volume for cancer diagnosis to PathologyWatch is a no-brainer,” said Austin Walters, founder and managing partner at SpringTide. “The company has worked hard to create a service that outperforms every other from both cost and quality perspectives.” “Dan is a driven entrepreneur with social good in mind,” said Ryan Brooks, principal at Blackbrook Management Group. “We are part of a cause, not just an investment capital endeavor. In the past, I have been a patient waiting for pathology to come back. When you are waiting for results that could change your life dramatically, you want doctors and tech you can depend on. PathologyWatch will enhance the human experience and enable dermatopathologists to do a better job.” “I am proud to support PathologyWatch’s mission to provide premier, accessible, and affordable digital pathology services to the world,” said Rick Stratford, Managing Director of Rock Creek Capital. “The ability to provide top-tier pathology services to all communities regardless of location brings hope to patients in underserved areas and can save countless lives. PathologyWatch and other digital platforms like it are democratizing healthcare services and bringing hope and change to our healthcare systems.” For more information about PathologyWatch, visit http://www.pathologywatch.com or contact info@pathologywatch.com. About PathologyWatch PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and in-house lab services. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.

Blueprint Health Investments

88 Investments

Blueprint Health has made 88 investments. Their latest investment was in PathologyWatch as part of their Series B on November 11, 2021.

CBI Logo

Blueprint Health Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/16/2021

Series B

PathologyWatch

$25M

Yes

17

6/13/2017

Seed

Referwell

$0.02M

Yes

2

6/7/2017

Seed VC

Blue Mesa Health

$0.75M

No

1

4/9/2016

Seed - II

Subscribe to see more

$99M

Subscribe to see more

10

2/7/2016

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/16/2021

6/13/2017

6/7/2017

4/9/2016

2/7/2016

Round

Series B

Seed

Seed VC

Seed - II

Seed

Company

PathologyWatch

Referwell

Blue Mesa Health

Subscribe to see more

Subscribe to see more

Amount

$25M

$0.02M

$0.75M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

17

2

1

10

10

Blueprint Health Portfolio Exits

11 Portfolio Exits

Blueprint Health has 11 portfolio exits. Their latest portfolio exit was Artemis Health on January 06, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/6/2022

Acquired

2

10/21/2021

Acquired

$99M

5

8/2/2021

Acquired

2

2/17/2021

Acquired

Subscribe to see more

Subscribe to see more

10

12/22/2020

Acquired

Subscribe to see more

Subscribe to see more

10

Date

1/6/2022

10/21/2021

8/2/2021

2/17/2021

12/22/2020

Exit

Acquired

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

5

2

10

10

Blueprint Health Partners & Customers

1 Partners and customers

Blueprint Health has 1 strategic partners and customers. Blueprint Health recently partnered with Sachs on July 7, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

7/28/2015

Partner

CRAINS-NEWYORK-horizontal-red-wht Carving up the East End Alliance. Blueprint Health, Sachs group launch partnership

The health care policy consulting firm announced it has created a partnership with accelerator Blueprint Health to create Junto Health .

2

Date

7/28/2015

Type

Partner

Business Partner

Country

News Snippet

CRAINS-NEWYORK-horizontal-red-wht Carving up the East End Alliance. Blueprint Health, Sachs group launch partnership

The health care policy consulting firm announced it has created a partnership with accelerator Blueprint Health to create Junto Health .

Sources

2

Blueprint Health Team

4 Team Members

Blueprint Health has 4 team members, including current Founding Partner, Mathew Slade Farkash.

Name

Work History

Title

Status

Allen Byerly

Founder

Current

Mathew Slade Farkash

Founding Partner

Current

Brad Weinberg

Founding Partner

Current

Taylor Mann

Founder

Former

Name

Allen Byerly

Mathew Slade Farkash

Brad Weinberg

Taylor Mann

Work History

Title

Founder

Founding Partner

Founding Partner

Founder

Status

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.